Table 1 Patient characteristics
Gefitinib (n = 55) | Erlotinib (n = 22) | |
|---|---|---|
Sex, n (%) | ||
Male | 19 (35) | 11 (50) |
Female | 36 (65) | 11 (50) |
Median age, years (range) | 71 (46–91) | 71 (47–83) |
ECOG PS, n (%) | ||
0–1 | 39 (71) | 18 (82) |
≧2 | 16 (29) | 4 (18) |
TNM stage, n (%) | ||
3B | 3 (5) | 1 (5) |
4 | 43 (78) | 16 (73) |
Recurrence | 9 (16) | 5 (23) |
Previous chemotherapy regimen, n (%) | ||
0 | 44 (80) | 9 (41) |
1 | 9 (16) | 7 (32) |
≧2 | 2 (4) | 6 (27) |
Brain metastasis, n (%) | ||
0 | 40 (73) | 10 (45) |
≧1 | 15 (27) | 12 (55) |
Radiotherapy for brain metastasis before EGFR-TKI treatment, n (%) | 4 (7) | 6 (27) |
WBRT | 1 (2) | 1 (4) |
SRT | 3 (5) | 5 (23) |
EGFR mutation, n (%) | ||
Exon19 del | 24 (44) | 6 (27) |
Exon21 L858R | 29 (53) | 15 (68) |
Minor | 2 (4) | 1 (5) |
Dose reduction or intermittent administration, n (%) | 13 (24) | 10 (45) |
Best response, n (%) | ||
CR | 0 (0) | 0 (0) |
PR | 24 (44) | 11 (50) |
SD | 20 (36) | 9 (41) |
PD | 4 (7) | 1 (5) |
Unknown | 7 (13) | 1 (5) |
The reason of EGFR-TKI discontinuation, n (%) | ||
Disease progression | 36 (65) | 17 (77) |
CNS progression | 10 (18) | 2 (9) |
Adverse event | 5 (9) | 2 (9) |
Other | 7 (13) | 1 (5) |
Ongoing | 7 (13) | 2 (9) |